Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.31 |
| ▸ | USP2 | O75604 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | HBB | P68871 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | PKM | P14618 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18099435 | 0.97 | USP2 (0.32) | MEN1KMT2AUSP2ALDH1A1CYP1A2 | |
| SCHEMBL18091463 | 0.95 | AKT1 (0.33) | MEN1KMT2AUSP2ALDH1A1CYP1A2 | |
| SCHEMBL25606356 | 0.94 | PRKDC (0.35) | MEN1KMT2AUSP2ALDH1A1CYP1A2 | |
| SCHEMBL13988310 | 0.92 | SLC6A3 (0.31) | — | |
| SCHEMBL1186032 | 0.92 | ALDH1A1 (0.32) | ALDH1A1 | |
| SCHEMBL18099433 | 0.90 | KCNH2 (0.31) | — | |
| SCHEMBL1189076 | 0.90 | PDK2 (0.33) | ALDH1A1CYP1A2CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL1007779 | 0.90 | PDK2 (0.33) | ALDH1A1CYP1A2CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL1188243 | 0.90 | ALDH1A1 (0.31) | ALDH1A1 | |
| SCHEMBL18099439 | 0.89 | HCRTR1 (0.32) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3071401-B9 | METHOD OF FORMING A PHOTOCHROMIC SEGMENTED MULTIFOCAL LENS | TRANSITIONS OPTICAL INC (US) | 2018-03-14 | — | — | EP | disclosed |
| EP-3071401-B1 | METHOD OF FORMING A PHOTOCHROMIC SEGMENTED MULTIFOCAL LENS | TRANSITIONS OPTICAL INC (US) | 2017-09-20 | — | — | EP | disclosed |
| US-9465234-B2 | Photochromic materials having extended pi-conjugated systems and compositions and articles including the same | JOHNSON & JOHNSON VISION CARE, INC. (US) | 2016-10-11 | — | — | US | disclosed |
| US-20150301357-A1 | PHOTOCHROMIC MATERIALS HAVING EXTENDED PI-CONJUGATED SYSTEMS AND COMPOSITIONS AND ARTICLES INCLUDING THE SAME | JOHNSON & JOHNSON VISION CARE (US) | 2015-10-22 | — | — | US | disclosed |
| US-9097916-B2 | Photochromic materials having extended pi-conjugated systems and compositions and articles including the same | JOHNSON & JOHNSON VISION CARE, INC. (US) | 2015-08-04 | — | — | US | disclosed |
| US-20140225049-A1 | PHOTOCHROMIC MATERIALS HAVING EXTENDED PI-CONJUGATED SYSTEMS AND COMPOSITIONS AND ARTICLES INCLUDING THE SAME | JOHNSON & JOHNSON VISION CARE, INC. (US) | 2014-08-14 | — | — | US | disclosed |
| US-8741188-B2 | Ophthalmic devices comprising photochromic materials having extended pi-conjugated systems | JOHNSON & JOHNSON VISION CARE, INC. (US) | 2014-06-03 | — | — | US | disclosed |
| US-20130065056-A1 | PHOTOCHROMIC MATERIALS HAVING EXTENDED PI-CONJUGATED SYSTEMS AND COMPOSITIONS AND ARTICLES INCLUDING THE SAME | JOHNSON & JOHNSON VISION CARE, INC. | 2013-03-14 | — | — | US | disclosed |
| US-8388872-B2 | Photochromic materials having extended pi-conjugated systems and compositions and articles including the same | TRANSITIONS OPTICAL, INC. (US) | 2013-03-05 | — | — | US | disclosed |
| US-20120145975-A1 | PHOTOCHROMIC MATERIALS HAVING EXTENDED PI-CONJUGATED SYSTEMS AND COMPOSITIONS AND ARTICLES INCLUDING THE SAME | TRANSITIONS OPTICAL, INC. (US) | 2012-06-14 | — | — | US | disclosed |
| US-8158037-B2 | Photochromic materials having extended pi-conjugated systems and compositions and articles including the same | JOHNSON & JOHNSON VISION CARE, INC. (US) | 2012-04-17 | — | — | US | disclosed |
| US-8147725-B2 | Photochromic materials having extended pi-conjugated systems and compositions and articles including the same | TRANSITIONS OPTICAL, INC (US) | 2012-04-03 | — | — | US | disclosed |
| US-20110042629-A1 | PHOTOCHROMIC MATERIALS HAVING EXTENDED PI-CONJUGATED SYSTEMS AND COMPOSITIONS AND ARTICLES INCLUDING THE SAME | TRANSITIONS OPTICAL, INC. (US) | 2011-02-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120145975-A1 | PHOTOCHROMIC MATERIALS HAVING EXTENDED PI-CONJUGATED SYSTEMS AND COMPOSITIONS AND ARTICLES INCLUDING THE SAME | IPO4, INTS6, INCENP | MEN1 3668/4885KMT2A 2530/4885USP2 4566/4885 |
| US-20130065056-A1 | PHOTOCHROMIC MATERIALS HAVING EXTENDED PI-CONJUGATED SYSTEMS AND COMPOSITIONS AND ARTICLES INCLUDING THE SAME | INCENP, INTS6, IPO4 | MEN1 3642/4885KMT2A 2760/4885USP2 4621/4885 |
| US-20110042629-A1 | PHOTOCHROMIC MATERIALS HAVING EXTENDED PI-CONJUGATED SYSTEMS AND COMPOSITIONS AND ARTICLES INCLUDING THE SAME | IPO4, INCENP, IPO11 | MEN1 3880/4885KMT2A 2187/4885USP2 4568/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.